The metabolism decrease
The risk or severity of adverse effects increase
The serum concentration increase
The serum concentration decrease
The therapeutic efficacy decrease
the central nervous system depressant ( CNS depressant ) activities increase
the QTc - prolonging activities increase
the hypotensive activities increase
The metabolism increase
the antihypertensive activities decrease
the hypoglycemic activities increase
the anticoagulant activities increase
The serum concentration of the active metabolites increase
the bradycardic activities increase
the serotonergic activities increase
The therapeutic efficacy increase
the hypokalemic activities increase
the orthostatic hypotensive activities increase
the cardiotoxic activities decrease
the excretion rate which could result in a higher serum level decrease
the atrioventricular blocking ( AV block ) activities increase
the sedative activities decrease
the tachycardic activities increase
the hypertensive and vasoconstricting activities increase
The risk or severity of QTc prolongation increase
the antihypertensive activities increase
the arrhythmogenic activities increase
the cardiotoxic activities increase
The risk or severity of hypotension increase
the bronchodilatory activities decrease
the hyperkalemic activities increase
the nephrotoxic activities increase
the hypertensive activities increase
the vasoconstricting activities increase
the neuroexcitatory activities increase
the anticoagulant activities decrease
the fluid increase
the antiplatelet activities increase
The serum concentration of the active metabolites reduce
the immunosuppressive activities increase
The risk or severity of bleeding increase
the stimulatory activities decrease
the vasoconstricting activities decrease
The risk or severity of myelosuppression increase
the thrombogenic activities increase
the anticholinergic activities increase
the analgesic activities increase
an increase in the absorption resulting in an increased serum concentration and potentially a worsening of adverse effects cause
The risk or severity of sedation and somnolence increase
The risk or severity of rhabdomyolysis increase
The risk or severity of hyperkalemia increase
the hepatotoxic activities increase
the respiratory depressant activities increase
the myopathic rhabdomyolysis activities increase
the vasopressor activities increase
a decrease in the absorption resulting in a reduced serum concentration and potentially a decrease in efficacy cause
the hyponatremic activities increase
the excretion rate which could result in a lower serum level and potentially a reduction in efficacy increase
The risk or severity of myopathy and rhabdomyolysis increase
the neuromuscular blocking activities decrease
The risk of a hypersensitivity reaction increase
the hypocalcemic activities increase
the vasodilatory activities increase
the myelosuppressive activities increase
the hyperglycemic activities increase
